We are one of the leading domestic manufacturers of high-quality medicinal products.

Established in 2004, certified in 2007 with WHO-GMP, in 2014 Davipharm reached first 100 registered products and started exporting its medicines to the Philippines and Cambodia. In 2017 Adamed Pharma S.A. acquired the controlling stake in Davipharm to upgrade the production standards, execute technology transfers, and develop export. In 2021 we opened the first certified HP Zone in Vietnam. Later that same year Davipharm had been certified with its first EU-GMP for the manufacturing operations (production and packing) of non-sterile products in capsules, hard shells and tablets. Since 2022 we have been focusing on the technology transfers. In 2023, Adamed acquired the remaining shares in Davipharm, becoming its sole shareholder. This acquisition infused Davipharm with a new vision centered on producing high-quality products adhering to EU-GMP standards and allowing the international expansion.

The integration with the Adamed Group plays a pivotal role in the company transformation. The harmonization of operational processes, sharing resources, learning from the best practices and following the corporate values, supports our efforts on the way to business excellence.

Our strategic goals include reaching a top position in the domestic market and becoming number 1 pharmaceutical exporting company in Vietnam, focusing on R&D excellence and new products launches, contract manufacturing, and close cooperation with academia to support products development and expand talent pools. Implementing ESG standards will ensure Davipharm’s position as a reliable and desired partner in the global supply chain.